The Group has obtained Series C investment of approximately RMB288 million
- Categories:The development course
- Author:
- Origin:
- Time of issue:2018-01-01 02:18
- Views:
(Summary description)
The Group has obtained Series C investment of approximately RMB288 million
(Summary description)
- Categories:The development course
- Author:
- Origin:
- Time of issue:2018-01-01 02:18
- Views:
Information
GT90001 (ALK-1 antibody) project has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 13th Five-Year Plan period
GT90001 (ALK-1 antibody) has been granted clinical trials permission from Taiwan Food and Drug Administration of China
The Suzhou production and R&D base has officially launched
The phase III clinical trial of GT0918 (Proxalutamide tablets) combined with Abiraterone for prostate cancer has been launched in China
The key phase III clinical trial of GT0918 (Proxalutamide tablets) as monotherapy for prostate cancer has been launched in China
The KX-826 (Pyrilutamide) project has been approved for clinical trials of hair loss indications by China and the United States
Suzhou Kintor has signed a cooperation agreement with Pfizer on the ALK-1 antibody project, and has been granted the first global exclusive license by Pfizer for developing a new antibody drug against tumor
The Group has obtained Series C investment of approximately RMB288 million
Scan the QR code to read on your phone